Combination MET- and EGFR-directed therapy in MET-overexpressing non-small cell lung cancers: time to move on to better biomarkers?
Transl Lung Cancer Res
.
2017 Jun;6(3):393-395.
doi: 10.21037/tlcr.2017.04.06.
Authors
Fernando C Santini
1
,
Siddharth Kunte
2
,
Alexander Drilon
1
3
Affiliations
1
Thoracic Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
2
Department of Internal Medicine, Mount Sinai St. Luke's West Hospital, New York, NY, USA.
3
Weill Cornell Medical College, New York, NY, USA.
PMID:
28713684
PMCID:
PMC5504114
DOI:
10.21037/tlcr.2017.04.06
No abstract available
Publication types
Editorial
Comment
Grants and funding
P30 CA008748/CA/NCI NIH HHS/United States